Drreddys Laboratories | RDY - Cash And Equivalent


Drreddys Laboratories reported INR18.66B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Cipla INR 7.96B 39.9M Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lonza CHF 1.11B 286M Dec/2024
Novartis USD 9.56B 2.9B Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
Prestige Brands USD 119.11M 20.4M Sep/2025
Richter Gedeon HUF 135.63B 61.59B Dec/2024
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025